The total costs associated with transcatheter aortic valve replacement (TAVR) were lower at 2 years than surgical aortic valve replacement (SAVR) in low-risk patients with severe aortic stenosis (AS), despite higher procedural costs, according to a new analysis of U.S. data from the PARTNER 3 trial.